We welcome you to Acne Treatment Center
....more
Updates on Effective Treatment For Acne
Patient claims acne medication caused Crohn's Disease and sues prescribing doctor - The Louisiana Record
 The Louisiana Record | Patient claims acne medication caused Crohn's Disease and sues prescribing doctor The Louisiana Record Herbert claims defendant Ricardo Mora, MD prescribed Accutane, a brand name for isotretinoin, to treat his acne in 2009. Herbert states he began suffering from dry, swollen lips, dry eyes and headaches and his acne became worse. |
Lasers redefine medical treatments - WKBT La Crosse
Lasers redefine medical treatments WKBT La Crosse From corrective eye surgery, skin rejuvenation and dental disorders to throat surgery, treatment of acne and birthmarks, and early detection of numerous types of cancer, lasers and related technologies are improving the quality of medical and surgical ... |
12 Beauty Essentials for 2012 - Huffington Post (blog)
12 Beauty Essentials for 2012 Huffington Post (blog) ($2.97, Trim Neatfeet Massaging Pumice Stone, Walmart) Lip brush for spot treatments -- A lip brush is the perfect way to apply spot treatments used for acne pimples or dark spots. The lip brush will allow for more precise application of the treatment. |
Justin Bieber Touting 'Proactiv' Products - Gather Celebs News Channel
 Gather Celebs News Channel | Justin Bieber Touting 'Proactiv' Products Gather Celebs News Channel Do you think the fact that he readily admits to having occasional issues with acne that it will make other teens feel less awkward about suffering from it themselves and seeking a reputable treatment? This might be one of the best advertising campaigns ... |
Shares of Syneron Medical Under Pressure, Down 2.2% - Financial News Network Online
Shares of Syneron Medical Under Pressure, Down 2.2% Financial News Network Online The Company's products include Aurora - Hair Removal, Skin Treatment and Acne treatment systems. Potential upside of 73.5% exists for Syneron Medical, based on a current level of $10.66 and analysts' average consensus price target of $18.50. |
